• 1
    Arvilommi P, Suominen KS, Mantere OK, Leppamaki S, Valtonen H, Isometsa ET. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry 2007; 68: 10210.
  • 2
    Calabrese JR, Shelton MD, Rapport DJ et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 215261.
  • 3
    Calabrese JR, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, Findling RL. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder. Eur Psychiatry 2005; 20: 925.
  • 4
    Muzina D. Rapid-cycling bipolar disorder: reviewing the evidence for pharmacologic interventions. CNS News 2006; January: 2732.
  • 5
    Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 (Suppl. 11): 227.
  • 6
    Calabrese JR, Shelton MD, Bowden CL et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62: 3441.
  • 7
    Muzina DJ, Shelton MD, Elhaj O et al. Impact of misdiagnosis in dual diagnosis rapid cycling bipolar disorder. Bipolar Disord 2005; 7: 27117, Abstract P66.
  • 8
    Schneck CD, Miklowitz DJ, Calabrese JR et al. Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry 2004; 161: 19028.
  • 9
    Calabrese JR, Suppes T, Bowden CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 84150.
  • 10
    Sanger TM, Tohen M, Vieta E et al. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affect Disord 2003; 73: 15561.
  • 11
    Vieta E, Calabrese JR, Hennen J et al. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry 2004; 65: 14208.
  • 12
    Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 2005; 89: 6977.
  • 13
    Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 24756.
  • 14
    Vieta E, Calabrese J, Goikolea J, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9: 41325.
  • 15
    Vieta E, Parramon G, Padrell E et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002; 4: 33540.
  • 16
    Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998; 18: 1724.
  • 17
    Gonzalez-Pinto A, Tohen M, Lalaguna B et al. Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharmacol 2002; 22: 4504.
  • 18
    Suppes T, Ozcan ME, Carmody T. Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disord 2004; 6: 32932.
  • 19
    Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol 1991; 11: 3967.
  • 20
    Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 3819.
  • 21
    Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 140011.
  • 22
    Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483: 4553.
  • 23
    Stark AD, Jordan S, Allers KA et al. Interaction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT (2A) receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007; 190: 37382.
  • 24
    Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002; 441: 13740.
  • 25
    Keck PE Jr, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 16518.
  • 26
    Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 53646.
  • 27
    Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripiprazole vs. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 23542.
  • 28
    Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 62637.
  • 29
    Keck P, Calabrese J, McIntyre R et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 148091.
  • 30
    Bowden C, Calabrese J, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392400.
  • 31
    Fagiolini A, Frank E, Houck PR et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63: 52833.
  • 32
    Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64: 142635.
  • 33
    Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 1127.
  • 34
    Coryell W, Solomon D, Turvey C et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003; 60: 91420.
  • 35
    Calabrese JR, Vieta E, El-Mallakh R et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004; 56: 95763.